Among the 47 Japanese patients who received brigatinib at the standard dose after progression from alectinib with or without history of crizotinib use, objective response rate (ORR) and disease control rate (DCR) were 34% (16 of 47) and 79% (37 of 47), respectively, with a median progression-free survival (PFS) of 7.3 months. READ ARTICLE
Journal of Thoracic Oncology DOI: 10.1016/J.JTHO.2020.11.023
Authors: Lianxi Song, Qinqin Xu, Analyn Lizaso, Yongchang Zhang,